Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | KIT |
Variant | Q556_W557del |
Impact List | deletion |
Protein Effect | gain of function - predicted |
Gene Variant Descriptions | KIT Q556_W557del results in the deletion of two amino acids in the juxtamembrane domain (exon 11) of the Kit protein from amino acids 556 to 557 (PMID: 16226710). Q556_W557del has not been characterized, however similar Kit exon 11 deletions are activating (PMID: 9438854, PMID: 15365079), and therefore, is predicted to lead to a gain of Kit protein function. |
Associated Drug Resistance | |
Category Variants Paths |
KIT mutant KIT act mut KIT exon 11 del KIT Q556_W557del KIT mutant KIT exon11 KIT exon 11 del KIT Q556_W557del |
Transcript | NM_000222.3 |
gDNA | chr4:g.54727434_54727439delCAGTGG |
cDNA | c.1666_1671delCAGTGG |
Protein | p.Q556_W557delQW |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_005265741 | chr4:g.54727431_54727436delGTACAG | c.1666_1671delGTACAG | p.V556_Q557delVQ | RefSeq | GRCh38/hg38 |
NM_001093772.2 | chr4:g.54727447_54727452delTTGAGG | c.1667_1672delTTGAGG | p.V556_E557delVE | RefSeq | GRCh38/hg38 |
NM_000222 | chr4:g.54727434_54727439delCAGTGG | c.1666_1671delCAGTGG | p.Q556_W557delQW | RefSeq | GRCh38/hg38 |
XM_017008179 | chr4:g.54727444_54727449delTTGTTG | c.1667_1672delTTGTTG | p.V556_V557delVV | RefSeq | GRCh38/hg38 |
NM_000222.2 | chr4:g.54727434_54727439delCAGTGG | c.1666_1671delCAGTGG | p.Q556_W557delQW | RefSeq | GRCh38/hg38 |
NM_001385285.1 | chr4:g.54727434_54727439delCAGTGG | c.1666_1671delCAGTGG | p.Q556_W557delQW | RefSeq | GRCh38/hg38 |
XM_017008179.1 | chr4:g.54727444_54727449delTTGTTG | c.1667_1672delTTGTTG | p.V556_V557delVV | RefSeq | GRCh38/hg38 |
NM_001385286.1 | chr4:g.54727447_54727452delTTGAGG | c.1667_1672delTTGAGG | p.V556_E557delVE | RefSeq | GRCh38/hg38 |
XM_005265742 | chr4:g.54727444_54727449delTTGTTG | c.1667_1672delTTGTTG | p.V556_V557delVV | RefSeq | GRCh38/hg38 |
NM_001385292.1 | chr4:g.54727444_54727449delTTGTTG | c.1667_1672delTTGTTG | p.V556_V557delVV | RefSeq | GRCh38/hg38 |
XM_005265740 | chr4:g.54727431_54727436delGTACAG | c.1666_1671delGTACAG | p.V556_Q557delVQ | RefSeq | GRCh38/hg38 |
NM_001385284.1 | chr4:g.54727431_54727436delGTACAG | c.1666_1671delGTACAG | p.V556_Q557delVQ | RefSeq | GRCh38/hg38 |
NM_001093772.1 | chr4:g.54727447_54727452delTTGAGG | c.1667_1672delTTGAGG | p.V556_E557delVE | RefSeq | GRCh38/hg38 |
XM_017008178.1 | chr4:g.54727434_54727439delCAGTGG | c.1666_1671delCAGTGG | p.Q556_W557delQW | RefSeq | GRCh38/hg38 |
NM_001385290.1 | chr4:g.54727431_54727436delGTACAG | c.1666_1671delGTACAG | p.V556_Q557delVQ | RefSeq | GRCh38/hg38 |
NM_001385288.1 | chr4:g.54727444_54727449delTTGTTG | c.1667_1672delTTGTTG | p.V556_V557delVV | RefSeq | GRCh38/hg38 |
XM_017008180.1 | chr4:g.54727447_54727452delTTGAGG | c.1667_1672delTTGAGG | p.V556_E557delVE | RefSeq | GRCh38/hg38 |
NM_001093772 | chr4:g.54727447_54727452delTTGAGG | c.1667_1672delTTGAGG | p.V556_E557delVE | RefSeq | GRCh38/hg38 |
XM_005265742.3 | chr4:g.54727444_54727449delTTGTTG | c.1667_1672delTTGTTG | p.V556_V557delVV | RefSeq | GRCh38/hg38 |
NM_000222.3 | chr4:g.54727434_54727439delCAGTGG | c.1666_1671delCAGTGG | p.Q556_W557delQW | RefSeq | GRCh38/hg38 |
XM_005265741.1 | chr4:g.54727431_54727436delGTACAG | c.1666_1671delGTACAG | p.V556_Q557delVQ | RefSeq | GRCh38/hg38 |
XM_017008180 | chr4:g.54727447_54727452delTTGAGG | c.1667_1672delTTGAGG | p.V556_E557delVE | RefSeq | GRCh38/hg38 |
XM_005265740.1 | chr4:g.54727431_54727436delGTACAG | c.1666_1671delGTACAG | p.V556_Q557delVQ | RefSeq | GRCh38/hg38 |
XM_017008178 | chr4:g.54727434_54727439delCAGTGG | c.1666_1671delCAGTGG | p.Q556_W557delQW | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KIT Q556_W557del | gastrointestinal stromal tumor | predicted - sensitive | Imatinib | Case Reports/Case Series | Actionable | In a clinical case study, Gleevec (imatinib) treatment resutled in a partial response in a patient with gastrointestinal stromal tumor harboring KIT Q556_W557del , with a progression-free survival of 26.8 months and an overall survival of 47 months (PMID: 18294292). | 18294292 |